DK3286176T3 - Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat - Google Patents
Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat Download PDFInfo
- Publication number
- DK3286176T3 DK3286176T3 DK16718016.5T DK16718016T DK3286176T3 DK 3286176 T3 DK3286176 T3 DK 3286176T3 DK 16718016 T DK16718016 T DK 16718016T DK 3286176 T3 DK3286176 T3 DK 3286176T3
- Authority
- DK
- Denmark
- Prior art keywords
- ureamalate
- crystallinic
- methylpiperidin
- cyanophenyl
- imidazol
- Prior art date
Links
- -1 4-CYANOPHENYL Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562152108P | 2015-04-24 | 2015-04-24 | |
| PCT/IB2016/052107 WO2016170451A1 (en) | 2015-04-24 | 2016-04-13 | Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3286176T3 true DK3286176T3 (da) | 2020-03-02 |
Family
ID=55806563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16718016.5T DK3286176T3 (da) | 2015-04-24 | 2016-04-13 | Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat |
| DK20151107.8T DK3666768T3 (da) | 2015-04-24 | 2016-04-13 | F r e m g a n g s m å d e t i l f r e m s t i l l i n g a f e n k r y s t a l l i n s k f o r m a f 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat; krystallinsk form af 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-YL)-1-methylpiperidin-4-YL)-3-(4-cyanophenyl)ure |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20151107.8T DK3666768T3 (da) | 2015-04-24 | 2016-04-13 | F r e m g a n g s m å d e t i l f r e m s t i l l i n g a f e n k r y s t a l l i n s k f o r m a f 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat; krystallinsk form af 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-YL)-1-methylpiperidin-4-YL)-3-(4-cyanophenyl)ure |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10414748B2 (enExample) |
| EP (2) | EP3666768B1 (enExample) |
| JP (1) | JP6345728B2 (enExample) |
| KR (2) | KR102078444B1 (enExample) |
| CN (1) | CN107531667A (enExample) |
| AR (1) | AR104391A1 (enExample) |
| AU (1) | AU2016251940C1 (enExample) |
| BR (1) | BR112017021075B1 (enExample) |
| CA (2) | CA2983387C (enExample) |
| CY (2) | CY1124056T1 (enExample) |
| DK (2) | DK3286176T3 (enExample) |
| ES (2) | ES2923593T3 (enExample) |
| HK (1) | HK1243416A1 (enExample) |
| HU (2) | HUE059506T2 (enExample) |
| IL (1) | IL255224B (enExample) |
| MX (1) | MX375384B (enExample) |
| PL (2) | PL3666768T3 (enExample) |
| PT (2) | PT3666768T (enExample) |
| RU (1) | RU2717564C2 (enExample) |
| SG (1) | SG11201707863QA (enExample) |
| SI (2) | SI3666768T1 (enExample) |
| TW (1) | TWI646093B (enExample) |
| WO (1) | WO2016170451A1 (enExample) |
| ZA (1) | ZA201706391B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017021075B1 (pt) | 2015-04-24 | 2021-08-03 | Pfizer Inc. | Forma cristalina de maleato de 1-((2r,4r)-2-(1h- benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4- cianofenil)ureia e composição farmacêutica |
| US20230107634A1 (en) * | 2020-01-28 | 2023-04-06 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof |
| EP4126237B1 (en) | 2020-03-26 | 2024-04-10 | LEK Pharmaceuticals d.d. | Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea |
| WO2023002362A1 (en) | 2021-07-22 | 2023-01-26 | Pfizer Inc. | Treatment of hematological malignancy |
| WO2023017541A1 (en) * | 2021-08-12 | 2023-02-16 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
| CN114668849B (zh) * | 2021-12-31 | 2024-01-23 | 中国人民解放军军事科学院军事医学研究院 | Shh通路调控生物节律及其相关应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US8253800B2 (en) | 2006-06-28 | 2012-08-28 | Nikon Corporation | Tracking device, automatic focusing device, and camera |
| ME00962B (me) * | 2007-06-29 | 2012-06-20 | Pfizer | Benzimidazolski derivati |
| BR112017021075B1 (pt) * | 2015-04-24 | 2021-08-03 | Pfizer Inc. | Forma cristalina de maleato de 1-((2r,4r)-2-(1h- benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4- cianofenil)ureia e composição farmacêutica |
-
2016
- 2016-04-13 BR BR112017021075-4A patent/BR112017021075B1/pt active IP Right Grant
- 2016-04-13 DK DK16718016.5T patent/DK3286176T3/da active
- 2016-04-13 EP EP20151107.8A patent/EP3666768B1/en active Active
- 2016-04-13 ES ES20151107T patent/ES2923593T3/es active Active
- 2016-04-13 SI SI201631561T patent/SI3666768T1/sl unknown
- 2016-04-13 DK DK20151107.8T patent/DK3666768T3/da active
- 2016-04-13 SI SI201630639T patent/SI3286176T1/sl unknown
- 2016-04-13 HU HUE20151107A patent/HUE059506T2/hu unknown
- 2016-04-13 PT PT201511078T patent/PT3666768T/pt unknown
- 2016-04-13 RU RU2017137269A patent/RU2717564C2/ru active
- 2016-04-13 KR KR1020177030098A patent/KR102078444B1/ko active Active
- 2016-04-13 PL PL20151107.8T patent/PL3666768T3/pl unknown
- 2016-04-13 AU AU2016251940A patent/AU2016251940C1/en active Active
- 2016-04-13 PL PL16718016T patent/PL3286176T3/pl unknown
- 2016-04-13 KR KR1020197009092A patent/KR20190038677A/ko not_active Withdrawn
- 2016-04-13 WO PCT/IB2016/052107 patent/WO2016170451A1/en not_active Ceased
- 2016-04-13 SG SG11201707863QA patent/SG11201707863QA/en unknown
- 2016-04-13 MX MX2017013645A patent/MX375384B/es active IP Right Grant
- 2016-04-13 HU HUE16718016A patent/HUE048664T2/hu unknown
- 2016-04-13 CN CN201680023699.0A patent/CN107531667A/zh active Pending
- 2016-04-13 PT PT167180165T patent/PT3286176T/pt unknown
- 2016-04-13 EP EP16718016.5A patent/EP3286176B1/en active Active
- 2016-04-13 HK HK18103046.8A patent/HK1243416A1/zh unknown
- 2016-04-13 US US15/567,433 patent/US10414748B2/en active Active
- 2016-04-13 CA CA2983387A patent/CA2983387C/en active Active
- 2016-04-13 ES ES16718016T patent/ES2774053T3/es active Active
- 2016-04-20 CA CA2927736A patent/CA2927736A1/en not_active Abandoned
- 2016-04-20 JP JP2016084307A patent/JP6345728B2/ja active Active
- 2016-04-22 TW TW105112723A patent/TWI646093B/zh active
- 2016-04-22 AR ARP160101150A patent/AR104391A1/es unknown
-
2017
- 2017-09-21 ZA ZA2017/06391A patent/ZA201706391B/en unknown
- 2017-10-24 IL IL255224A patent/IL255224B/en active IP Right Grant
-
2019
- 2019-07-25 US US16/521,742 patent/US11168066B2/en active Active
-
2020
- 2020-02-19 CY CY20201100155T patent/CY1124056T1/el unknown
-
2021
- 2021-10-06 US US17/494,938 patent/US11891373B2/en active Active
- 2021-10-06 US US17/494,923 patent/US11891372B2/en active Active
-
2022
- 2022-07-06 CY CY20221100461T patent/CY1125333T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1009I2 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| DK3704120T3 (da) | Heterocykliske forbindelser som prmt5-inhibitorer | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| EP3652329A4 (en) | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| EA201891211A1 (ru) | Ингибиторы cxcr2 | |
| HUE059945T2 (hu) | Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| MA41014A (fr) | Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique | |
| MA42623A (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| DK3319939T3 (da) | Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer | |
| DK3286176T3 (da) | Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat | |
| EP3377060A4 (en) | PYRAZOL COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| LT4084779T (lt) | 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos | |
| IL252900B (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
| DK3458460T3 (da) | Imidazoler som histondemethylase-inhibitorer | |
| LT3265459T (lt) | Amidų junginiai, kaip 5-ht4 receptorių agonistai | |
| DK3390456T3 (da) | Fremgangsmåde til fremstilling af parenchymcellecellulose | |
| EP3954390C0 (en) | TRANSDUCTION BUFFER | |
| HUE063043T2 (hu) | Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására | |
| DK3099302T3 (da) | Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid | |
| EP3337804A4 (en) | BIOKON JUGATE OF HETEROCYCLIC COMPOUNDS | |
| DK3458467T3 (da) | Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener |